Talphera Executives to Outline Clinical Strategy in New York

Talphera, Inc. is positioning its lead product candidate, Niyad, as a central pillar of its presentation to investors. Currently under investigation as an anticoagulant for the extracorporeal circuit, the lyophilized formulation of nafamostat holds Breakthrough Device Designation from the U.S. Food and Drug Administration. The company operates under an investigational device exemption as it continues to refine its therapeutic offerings for medically supervised settings.

The presentation is set for 4:30 p.m. ET. Beyond the public discussion, Angotti and Aslam are scheduled to hold individual meetings with conference attendees. Investors unable to attend the session in person can access a live webcast through the company’s investor relations portal. A recording of the event will remain accessible online for 90 days following the conclusion of the conference.